By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile

 

Neurocrine Biosciences, Inc. 

12790 El Camino Real

San Diego  California  92121  U.S.A.
Phone: 858-617-7600 Fax: 858-617-7601


SEARCH JOBS








Company News
Neurocrine (NBIX) Announces Presentations Related To INGREZZA (Valbenazine) Capsules At The 21st International Congress Of Parkinson's Disease And Movement Disorders 6/2/2017 11:34:03 AM
Neurocrine (NBIX) Tanks as Tourette Syndrome Drug Flunks Mid-Stage Study 5/24/2017 5:50:37 AM
Neurocrine Biosciences (NBIX) Reports First Quarter 2017 Results 5/10/2017 10:27:54 AM
Neurocrine Biosciences (NBIX) Announces Conference Call And Webcast To Report First Quarter 2017 Results 5/4/2017 9:18:26 AM
Neurocrine Biosciences (NBIX) Announces Closing Of Offering Of $517.5 Million Of Convertible Senior Notes 5/3/2017 8:29:30 AM
Neurocrine Biosciences (NBIX) Prices $450.0 Million Convertible Senior Notes Offering 4/27/2017 7:32:02 AM
Neurocrine Biosciences (NBIX)’ New Drug May Cost Patients More Than $10,000 A Month, Twice As Much As Expected 4/27/2017 6:30:39 AM
Neurocrine Biosciences (NBIX) Announces Proposed Convertible Senior Notes Offering 4/26/2017 8:56:48 AM
Nothing's Gonna Stop Neurocrine Biosciences (NBIX) Now: Shares Jumped on FDA Approval of the First and Only Drug to Treat Tardive Dyskinesia for Adults 4/12/2017 7:00:55 AM
Neurocrine Biosciences (NBIX) Announces American Journal Of Psychiatry Publication Of Positive Results From Kinect 3 Phase III Study Of INGREZZA TM (Valbenazine) For The Treatment Of Tardive Dyskinesia 3/21/2017 7:31:49 AM
12345678910...
//-->